Y-mAbs Therapeutics (YMAB) - חוב לטווח ארוך להון

The current market quotes for Y-mAbs Therapeutics (YMAB) visualized below on GURU.Markets reflect the price action of a company that adheres to bioethics in pediatric testing and environmental standards for waste disposal. The business is actively scaling its commercial reach by expanding its pipeline of treatments for pediatric tumors. Yields reaching 0.03 are supported by the commercialization of radio-immunotherapeutic antibodies and milestone payments from partners for research success.

This indicator determines the issuer's long-term solvency by comparing liabilities with maturities exceeding one year against the size of total equity. By analyzing the long-term debt-to-equity chart, an investor assesses default risk against expansion potential, which is critical for the research-intensive business of Y-mAbs Therapeutics (YMAB) when financing costly developments in pediatric oncology and retaining rare specialists through grants.